| Project/Area Number |
18590337
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
SUZUKI Toshimitsu Fukushima Medical University, Department of Pathology, professor (80018952)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HOSHI Nobuo Fukushima Medical University, Department of Pathobgy, assistant (70274959)
KUSAKABE Takashi Fukushima Medical University, Department of Pathobgy, assistant (10325954)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,930,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥330,000)
Fiscal Year 2007: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2006: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
|---|
| Keywords | LXRα / human cancer cell lines / LXR α m RNA / immunohistochemistry / RXR / SREBP-1c / iRNA / LXRα aeonist / SREBP-1 / 脂肪酸合成酵素 / グルコーストランスポーター |
|---|
| Research Abstract |
In the present research, we examined expression of LXR α in human cancer cell lines and in some resected human cancers.
1. Expression of LXR α in human cancer cell lines
Immunohistochemical examination revealed expression of LXR α in five cell lines among eight gastric cancer cell lines.Pancereatic cancer cell lines (n=4), one melanoma cell line and one myeloma cell line lacked LXR α LBD expression.
2. Expression of LXR a in human cancers
One case in lung carcinoma (n=55), two cases in seminomas/dysgerminomas (n=42)and two cases in gastric carcinomas (n=30) showed positivity for LXR α.
3. Expression of LXR amRNA
Three gastric cancer cell lines examined (KATOM, MKN28 and MKN45)expressed LXR α mRNA. Accordingly. mRNA for RXRα/β,PEAR α, SREBP1c/la were detected in MKN28 cells. This implies that at least in MKN28, pathway from LXR α -RXR-SREBP1c to PPAR α has been established.
4. Inhibition of LXR α expression by iRNA in MKN28 caused no morphological change and growth rate of the cells.
5. Preliminarily, antagonist of LXR α (T0901317)induced growth retardation of MKN28 cells. In conclusion, expression of LXR α in human cancers is rare event but overexpressed LXR a might be a target of cancer therapy.
|
